CASI Pharmaceuticals Inc. (CASI): Prakiraan wutah bathi kanggo taun ngarep

The projected net profit growth rate for n+1 demonstrates an expansion phase for CASI Pharmaceuticals through the licensing of new oncology assets, with the parameter stabilizing at 0.00. Business profitability is based on the commercialization of hematological drugs from foreign partners in China. The strategy to capture the Asian biomedical market relies on exclusive agreements with Western laboratories and local expertise.

CASI: Prakiraan wutah bathi saben saham kanggo taun ngarep CASI Pharmaceuticals Inc. 04.07.2022 - 14.03.2026

CASI (CASI Pharmaceuticals, Inc.): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Bagan rega CASI Pharmaceuticals Inc.|CASI - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Kapitalisasi pasar CASI Pharmaceuticals|CASI - Nilai Bisnis

- indikator kapitalisasi buku:

Nilai Buku saben Saham CASI Pharmaceuticals|CASI - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku casipharmaceuticals.com|CASI - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Utang marang Ekuitas CASI Pharmaceuticals|CASI - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal CASI Pharmaceuticals Inc.|CASI - Gunggung kewajiban utang perusahaan|Utang marang nilai buku CASI Pharmaceuticals|CASI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan CASI Pharmaceuticals|Rasio cepet casipharmaceuticals.com

- informasi bathi lan kelipatan valuasi:

CASI - Bathi pungkasan|Proyeksi bathi mangsa ngarep CASI Pharmaceuticals|CASI - Pangali P/E|Rega marang bathi mangsa ngarep CASI Pharmaceuticals Inc.|CASI - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CASI Pharmaceuticals|CASI - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) CASI Pharmaceuticals|CASI - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan casipharmaceuticals.com|CASI - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep CASI Pharmaceuticals

Analisis wiwitan perusahaan:CASI Pharmaceuticals

CASI Pharmaceuticals revenues depend on the sales of international partners' oncology drugs in the Chinese market. This shift in the consensus net profit growth estimate captures the trend of expert expectations regarding the future efficiency of these sales. While the indicator's growth reflects market optimism, extreme peaks often precede a price correction, signaling that the business's fundamental valuation has reached its ceiling.

Analisis pesaing CASI Pharmaceuticals